Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI110968

Modulation of the hydro-osmotic effect of vasopressin on the rabbit cortical collecting tubule by adrenergic agents

Radha K. Krothapalli, W. Brian Duffy, Harry O. Senekjian, and Wadi N. Suki

Department of Medicine, Baylor College of Medicine, Methodist Hospital and Veterans Administration Medical Center, Houston, Texas 77211

Find articles by Krothapalli, R. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, Methodist Hospital and Veterans Administration Medical Center, Houston, Texas 77211

Find articles by Duffy, W. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, Methodist Hospital and Veterans Administration Medical Center, Houston, Texas 77211

Find articles by Senekjian, H. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, Methodist Hospital and Veterans Administration Medical Center, Houston, Texas 77211

Find articles by Suki, W. in: PubMed | Google Scholar

Published July 1, 1983 - More info

Published in Volume 72, Issue 1 on July 1, 1983
J Clin Invest. 1983;72(1):287–294. https://doi.org/10.1172/JCI110968.
© 1983 The American Society for Clinical Investigation
Published July 1, 1983 - Version history
View PDF
Abstract

The effects of catecholamines on antidiuretic hormone ([Arg8]-vasopressin [AVP])-induced water absorption were evaluated in cortical collecting tubules isolated from the rabbit kidney and perfused in vitro. In the presence of AVP (100 μU/ml), net fluid volume absorption (Jv, nanoliters per minute per millimeter) was 1.14±0.12 and osmotic water permeability coefficient (Pf, X 10-4 centimeters per second) was 217.3±39.9. The addition of the alpha-adrenergic agonist, phenylephrine (PE), in a concentration of 10-6 M resulted in a significant decrease in Jv and Pf to 0.83±0.13 (P < 0.001) and 148.8±41.8 (P < 0.02), respectively. Increasing the concentration of PE to 10-5 M resulted in a further decrease in Jv and Pf to 0.53±0.05 (P < 0.05 vs. PE 10-6 M) and 88.5±9.0 (P 0.05 vs. PE 10-6 M), respectively. In a separate group of tubules, in the presence of AVP (100 μU/ml) and PE (10-5 M), Jv and Pf were 0.35±0.07 and 66.0±17.3, respectively. The addition of the alpha-adrenergic antagonist, phentolamine (PH), in a concentration of 10-6 M resulted in a significant increase in Jv to 1.07±0.19 (P < 0.001) and Pf to 193.3±35.9 (P < 0.005). PH (10-5 M) alone did not significantly affect Jv and Pf in the presence of AVP (100 μU/ml) nor in the presence of 8-bromo adenosine 3',5' cyclic monophosphate (8-BrcAMP). Jv and Pf were 1.20±0.21 and 174.0±25.8, respectively, in the presence of 8-BrcAMP (10-4 M).

We next examined the effect of the beta-adrenergic agonist, isoproterenol (ISO), on Jv and Pf in the presence of AVP. Jv and Pf were 1.04±0.10 and 202.6±17.2, respectively, in the presence of AVP (100 μU/ml) and 1.06±0.18 and 193.4±27.7, respectively, in the presence of AVP (10μU/ml). However, in the presence of AVP in a concentration of 2.5 μU/ml, Jv was 0.60±0.07 and Pf was 100.7±24.7. ISO (10-6 and 10-5 M) did not have any significant effect in the presence of the above maximal and submaximal concentrations of AVP. In the absence of AVP, control Jv was 0.01±0.12 and Pf was 4.6±11.0. The addition of ISO at 25 or 37°C did not result in any significant change in Jv or Pf.

These studies indicate that alpha-adrenergic agonists directly inhibit AVP-mediated water absorption at the level of the tubule, an effect that can be blocked by a specific alpha-adrenergic antagonist. This effect appears to be exerted at the level of activation of adenylate cyclase since it is absent in the presence of cAMP. The beta-adrenergic agonists do not directly inhibit or enhance AVP-mediated water absorption at the level of the renal tubule.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 287
page 287
icon of scanned page 288
page 288
icon of scanned page 289
page 289
icon of scanned page 290
page 290
icon of scanned page 291
page 291
icon of scanned page 292
page 292
icon of scanned page 293
page 293
icon of scanned page 294
page 294
Version history
  • Version 1 (July 1, 1983): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts